Back

Topical application of a skin serum with Progerin inhibitor helps alleviate human skin aging

Kang, S.-m.; Kim, M.; Woo, T.-G.; Park, S.; Kim, B.-H.; Park, B.-J.

2025-09-12 dermatology
10.1101/2025.09.10.25335131 medRxiv
Show abstract

Skin aging is a complex process driven by intrinsic and extrinsic factors, resulting in structural and functional changes such as reduced elasticity, hydration loss, and the appearance of wrinkles. This study evaluates the efficacy and safety of a topical formulation with common skincare ingredients and a Progerin inhibitor, which is designed to combat multiple signs of skin aging. A 4-week clinical trial was conducted with 21 female participants aged 30-50. The study measured key parameters of skin health, including crows feet wrinkle reduction, facial lifting improvement, skin hydration, elasticity, density, and tone brightness. Objective assessments, including dermatological evaluations and quantitative measurements, were complemented by subjective feedback from participants through efficacy and preference surveys. The results demonstrated significant improvements across all evaluated parameters. After 4 weeks of use, participants exhibited a 5.631% reduction in wrinkles, a 3.234% improvement in facial lifting, an 18.435% increase in skin hydration, an 8.563% enhancement in elasticity, a 3.424% improvement in skin tone brightness, and a 23.583% increase in skin density (p < 0.05). No adverse reactions were reported, and the product was well-tolerated. Participant surveys further confirmed high levels of satisfaction with the skin serums performance and usability. These findings indicate that the progerin inhibitor effectively improves multiple signs of skin aging, especially skin density increase, and supports its potential as a comprehensive anti-skin aging ingredient. This study contributes to advancing topical skincare formulations aimed at rejuvenating and maintaining healthy, youthful skin. Research ObjectiveThis study aimed to evaluate the effects of a skin serum containing a 1 % progerin inhibitor on eye wrinkles, facial lifting, skin moisturizing, skin elasticity, skin density, and skin tone brightness in women aged 30 to 55. The test was conducted by measuring the relevant test items before product use, and at 2 weeks and 4 weeks after use. After the trial was completed, effectiveness and preference surveys were conducted.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Frontiers in Nutrition
23 papers in training set
Top 0.1%
27.3%
2
PLOS ONE
4510 papers in training set
Top 8%
19.6%
3
Frontiers in Medicine
113 papers in training set
Top 0.3%
8.9%
50% of probability mass above
4
Frontiers in Public Health
140 papers in training set
Top 0.6%
6.7%
5
Scientific Reports
3102 papers in training set
Top 21%
5.1%
6
Experimental Dermatology
10 papers in training set
Top 0.1%
3.8%
7
PLOS Neglected Tropical Diseases
378 papers in training set
Top 3%
1.8%
8
Aging
69 papers in training set
Top 2%
1.4%
9
eClinicalMedicine
55 papers in training set
Top 0.9%
1.3%
10
Cureus
67 papers in training set
Top 4%
1.0%
11
Journal of Advanced Research
15 papers in training set
Top 0.5%
0.9%
12
International Journal of Biological Macromolecules
65 papers in training set
Top 3%
0.9%
13
BMC Cancer
52 papers in training set
Top 2%
0.9%
14
eLife
5422 papers in training set
Top 52%
0.9%
15
JAMA Network Open
127 papers in training set
Top 4%
0.8%
16
Aging Cell
144 papers in training set
Top 3%
0.8%
17
Frontiers in Plant Science
240 papers in training set
Top 5%
0.8%
18
International Journal of Environmental Research and Public Health
124 papers in training set
Top 7%
0.8%
19
Advanced Science
249 papers in training set
Top 21%
0.7%
20
International Journal of Molecular Sciences
453 papers in training set
Top 17%
0.7%
21
Nature Communications
4913 papers in training set
Top 65%
0.7%
22
PLOS Medicine
98 papers in training set
Top 5%
0.5%
23
Journal of Investigative Dermatology
42 papers in training set
Top 0.7%
0.5%